• Conference
  • Earn CE
  • Free Samples
  • Magazine
  • Subscribe
  • Videos
    • Recent Quotes
    My Watchlist
    Indicators
    Dental Market Index
    Markets
    Stocks
    ETFs
    Tools
    Markets:
    Overview
    News
    Currencies
    International
    Treasuries

    Dianthus Therapeutics, Inc. - Common Stock (NQ:DNTH)

    85.74 -0.41 (-0.48%)
    Streaming Delayed Price Updated: 4:00 PM EDT, May 13, 2026 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    All News about Dianthus Therapeutics, Inc. - Common Stock

    < Previous 1 2 3 4 Next >
    News headline image
    Why This Biotech Fund Added $7 Million to an Oncology Stock Up 120% ↗
    This biotech specializes in small molecule kinase inhibitors for cancer, with lead drug candidates in early-stage clinical trials. 
    Via The Motley Fool
    Topics Regulatory Compliance
    News headline image
    Why This Biotech Fund Opened a $9 Million Position in a Newly Public Cancer Company ↗
    This clinical-stage biotech develops targeted radiopharmaceutical therapies for cancer using a proprietary miniprotein platform. 
    Via The Motley Fool
    Topics Initial Public Offering Regulatory Compliance
    News headline image
    Why This Biotech Fund Increased Its Oruka Therapeutics Stake Amid a Staggering 500% Rally ↗
    This clinical-stage biotech develops monoclonal antibody therapies targeting psoriasis and other immunology indications. 
    Via The Motley Fool
    Topics Regulatory Compliance
    News headline image
    Dianthus Therapeutics Highlights Recent Business Achievements and Reports Q1 2026 Financial Results
    From Dianthus Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Dianthus Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
    From Dianthus Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Dianthus Therapeutics' (DNTH) CFO Sold 8,224 Shares for $739,000 ↗
    This clinical-stage biotech focused on monoclonal antibody therapies reported a notable insider sale in its latest SEC filing. 
    Via The Motley Fool
    Topics Regulatory Compliance
    News headline image
    Dianthus Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
    From Dianthus Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Dianthus Therapeutics CFO Sells $9.5 Million in Stock ↗
    This biotech firm developing antibody therapies for rare diseases disclosed a significant insider sale amid rapid share price gains. 
    Via The Motley Fool
    Topics Regulatory Compliance
    News headline image
    Biotech Stock Jumps 288% Amid Massive Raise as One Early Backer Reports $14 Million Exit ↗
    Clinical-stage biotech Dianthus Therapeutics develops antibody therapies for severe autoimmune and neuromuscular conditions. 
    Via The Motley Fool
    News headline image
    Dianthus Therapeutics, Inc. Announces Closing of its Upsized $719 Million Underwritten Public Offering Including Full Exercise of Underwriters’ Option to Purchase Additional Shares
    From Dianthus Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Complementing the Future: A Deep Dive into Dianthus Therapeutics (DNTH) After Its Phase 3 Breakthrough
    Date: March 12, 2026 Introduction Dianthus Therapeutics (NASDAQ: DNTH) has become the center of Wall Street’s attention today, with its share price surging 19.4% in early trading following a pivotal... 
    Via Finterra
    Topics Economy
    News headline image
    Dianthus Therapeutics, Inc. Announces Pricing of Upsized $625 Million Underwritten Public Offering
    From Dianthus Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Dianthus Therapeutics, Inc. Announces Proposed $400 Million Underwritten Public Offering
    From Dianthus Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    DNTH Stock Soars After Early ‘Go’ Decision For Drug In Autoimmune Disorder Program, Boosting Wall Street Optimism For Potential Launch ↗
    Dianthus Therapeutics announced an early “go” decision for its experimental drug claseprubart in its Chronic Inflammatory Demyelinating Polyneuropathy program based on analysis of data from a part of... 
    Via Stocktwits
    Gapping stocks in Monday's session ↗
    Via Chartmill
    News headline image
    Dianthus Therapeutics Highlights Recent Business Achievements, Including GO Decision for Phase 3 CAPTIVATE CIDP Trial, and Reports Q4 and FY 2025 Financial Results
    From Dianthus Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Dianthus Therapeutics Announces Early GO Decision Following Interim Responder Analysis in Phase 3 CAPTIVATE Trial of Claseprubart in Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
    From Dianthus Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Dianthus Therapeutics to Host Conference Call and Webcast to Discuss the Interim Responder Analysis Results of the Phase 3 Captivate Trial of Claseprubart in Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
    From Dianthus Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Dianthus Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
    From Dianthus Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Dianthus Therapeutics to Participate in The TD Cowen 46th Annual Health Care Conference
    From Dianthus Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    The Great Rotation: Small-Caps Break the Mega-Cap Monopoly in Early 2026
    The financial landscape of 2026 has opened with a dramatic shift in market leadership, as small-cap stocks stage a historic rally that has left large-cap tech giants in the rearview mirror. After years... 
    Via MarketMinute
    Topics Artificial Intelligence Earnings Economy
    News headline image
    Dianthus Therapeutics to Participate in the Guggenheim Emerging Outlook: Biotech Summit 2026
    From Dianthus Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Dianthus CFO Sells 20,000 Shares for $903,600 After Massive Year-End Run ↗
    This biotech developing therapies for rare autoimmune diseases reported notable insider selling in its most recent SEC disclosure. 
    Via The Motley Fool
    Topics Regulatory Compliance
    News headline image
    Dianthus Therapeutics To Participate in the 44th Annual J.P. Morgan Healthcare Conference
    From Dianthus Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Leads Biolabs And Dianthus Therapeutics Announce Initiation of Phase 1 Trial Of LBL-047 (DNTH212) In Healthy Volunteers and Patients With Systemic Lupus Erythematosus (SLE)
    From Dianthus Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Dianthus Therapeutics To Participate in the 8th Annual Evercore Healthcare Conference
    From Dianthus Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Dianthus Therapeutics Highlights Recent Business Achievements and Reports Q3 Financial Results
    From Dianthus Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Dianthus Therapeutics to Participate in Four Investor Conferences During November
    From Dianthus Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Dianthus Therapeutics Highlights New Claseprubart Data Presented During 2025 AANEM Annual Meeting
    From Dianthus Therapeutics, Inc.
    Via GlobeNewswire
    News headline image
    Dianthus Therapeutics Announces Exclusive License Agreement with Leads Biolabs for DNTH212, a First and Potentially Best-In-Class, Phase 1 Ready Bifunctional BDCA2 & BAFF/APRIL Inhibitor for Severe Autoimmune Diseases
    From Dianthus Therapeutics, Inc.
    Via GlobeNewswire
    < Previous 1 2 3 4 Next >
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the Privacy Policy and Terms Of Service.
    © 2025 FinancialContent. All rights reserved.